Colorectal cancer (CRC) remains one of the leading causes of cancer‑related deaths worldwide. The condition’s high incidence and generally poor prognosis impose a major threat to public health and a substantial social and economic burden. Given these impacts, improving the accuracy of early diagnosis and the effectiveness of treatment strategies for CRC is of notable importance. The referenced review synthesizes research on aptamers as emerging tools to address those needs.
Aptamers are short nucleotide ligands selected for high affinity and specificity to target molecules. They are valued for programmability, enabling design and optimization for particular diagnostic or therapeutic functions. The SELEX aptamer technique is the principal method for isolating aptamers with desired binding properties; SELEX is specifically indexed in the article’s MeSH terms. The review highlights these inherent advantages as the rationale for exploring aptamers in CRC applications.
In CRC research, aptamers are exploited primarily for their ability to bind selectively to receptors and other molecular structures on the surface of cancer cells. By recognizing and attaching to such targets, aptamers can be used both to detect tumor‑associated molecules and to interfere with receptor activity. The capacity of aptamers to inhibit receptor function represents a mechanism through which they may modulate cancer cell behavior and thereby contribute to therapeutic strategies.
One major branch of the published work organizes aptamer research around diagnostic detection. Aptamers have been investigated as recognition elements for tumor biomarkers, taking advantage of their high specificity to improve detection accuracy. The review places diagnostic studies alongside therapeutic research in order to assess comparative translational value, though the PubMed abstract does not provide details on individual assays, analytic performance metrics, or clinical validation studies. Overall, the synthesis emphasizes the potential of aptamer‑based approaches to augment early detection of CRC.
A second major branch covered in the review relates to targeted therapy. In this context, aptamers can be designed to bind cell‑surface receptors on colorectal cancer cells and to interfere with receptor‑mediated signaling, thereby exerting direct anti‑tumor effects. The MeSH indexing also situates this work within the broader concept of molecular targeted therapy. The review collates studies that explore aptamer‑mediated interventions, evaluating how receptor targeting might translate into clinically relevant therapeutic strategies. Specific therapeutic sequences, dosing, or outcome data are not described in the abstract and therefore are not summarized here.
The authors organize relevant research achievements into the two principal categories of diagnostic detection and targeted therapy to systematically assess translational value. The review aims to provide a new scientific basis and potential methods for diagnosing and treating CRC using aptamers. While the abstract underscores translational intent, it does not enumerate particular clinical trials, regulatory statuses, or quantitative translational milestones. The MeSH terms associated with the review include both animal and human research contexts, indicating that the literature surveyed spans preclinical and clinical domains, but explicit stage‑by‑stage mappings were not provided in the abstract.
The review concludes that aptamers possess substantial potential for tumor‑targeted diagnosis and treatment in CRC due to their high affinity, high specificity, and programmability. By targeting surface receptors on cancer cells and, where applicable, inhibiting receptor activity, aptamers represent promising tools to improve early diagnosis and enable targeted therapeutic interventions. The article serves to collate current achievements and to outline scientific foundations for future work aimed at translating aptamer‑based technologies into clinical practice. The PubMed abstract does not supply granular experimental or clinical outcome data; readers seeking sequence‑level, performance, or trial information should consult the full text of the review (Mol Med Rep. 2026 Nov;34(5):301; PMID 42725398; DOI 10.3892/mmr.2026.14012).